NCE-1 Intelligence & Market Opportunity

Camzyos

Mavacamten

Cardiovascular agent

Oral Capsule

Approval Date

28-Apr-22

NCE-1 Date

28-Apr-26

NCE Date

28-Apr-27

Commercial snapshot

Market performance & projections

Revenue ($M)

1068

CAGR (%)

0.2301

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1428

2027

1801

2028

2146

2029

2445

2030

2683

2031

2858

2032

3014

Molecule profile

Details & specifications

Molecule

Mavacamten

Innovator

MYOKARDIA, INC.

Dosage Form

Oral Capsule

Strength

2.5 mg, 15 mg, 5 mg, 10 mg

Therapeutic Category

Cardiovascular agent

Usage

To treat certain classes of obstructive hypertrophic cardiomyopathy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.